The 21st edition of BioAsia, a flagship healthcare and life sciences event organized by the Government of Telangana, is gearing up for its grand launch in Hyderabad. Scheduled to take place from February 26 to 28, 2024, at the Hyderabad International Convention Center (HICC), the three-day forum is expected to host over 3000 delegates from 50 countries. Sridhar Babu Duddilla, Minister for Information Technology, Industries & Commerce of the state, has recently conducted a thorough review of the preparations for this global conference.
BioAsia, a flagship healthcare and life sciences event, was established with a visionary mission to elevate, empower, and stimulate innovations, pioneering discoveries, and effective solutions within the biotechnology industry. Serving as a dynamic global platform, BioAsia brings together key stakeholders, including Biotech & Biopharma Companies, research institutions, academia, investors, service providers, policymakers, regulators, and analysts.
The primary focus of BioAsia is to propel industry growth by creating an effective environment that fosters collaborations, joint ventures, mergers and acquisitions. The platform is dedicated to facilitating knowledge and experience sharing among global industry players to benefit all stakeholders. BioAsia actively promotes innovations and initiatives through prestigious awards and recognitions while playing a crucial role in advocating issues to policymakers and charting the roadmap for the biotechnology sector.
BioAsia operates as a dynamic showcase for companies to exhibit, launch, and highlight their unique strengths, products, and services. Acting as a key catalyst, BioAsia mobilizes all necessary elements to drive the growth of the emerging biotechnology industry and optimize the vast business potential within the biotech landscape. On a broader scale, BioAsia is actively contributing to a global transformation, shifting the focus from the treatment of illness to a broader perspective of wellness. With its comprehensive approach and commitment to excellence, BioAsia stands as a driving force in shaping the future of the biotechnology industry and promoting a holistic approach to health and well-being.
As one of the significant players in steering the life sciences development journey in India, BioAsia has emerged as a crucial event, redirecting focus towards industry advancements and challenges. The event aims to explore the theme of “Data & AI: Redefining Possibilities,” bringing together global leaders, scientists, regulatory bodies, industry associations, and academia over three days of discussions, deliberations, and networking.
The 21st edition consists of a lineup of over 70 influential speakers, including global CEOs and industry leaders. Keynote speakers announced for the event include David Ricks, CEO, Eli Lilly and Company, Christopher Boerner, Incoming CEO, Bristol Myers Squibb, Geoff Martha, Chairman and CEO, Medtronic, and Gregg Semenza, Nobel Laureate & Professor at Johns Hopkins School of Medicine, among others. Notable participants also include Stefan Kaufmann, President and CEO, Olympus, Rod Hochman, CEO, Providence, and Stefan Stoffel, Global Operating Partner, Advent International.
Expectations are high, with BioAsia 2024 projected to attract more than 3000 participants, providing a dynamic platform for networking and collaboration. The event will feature an expanded exhibition hosting over 200 companies showcasing groundbreaking advancements and cutting-edge products in the life sciences and biotechnology sector.
Sridhar Babu, Minister for Industries & Commerce Dept., Government of Telangana, expressed his enthusiasm for the growing global stature of BioAsia. He stated, “BioAsia has emerged as a critical instrument for the development of the Indian and global Life-Sciences and allied industries over the last two decades. We are thrilled to announce that several global CEOs will be attending BioAsia for the first time, underlining the event’s rising prominence on the international stage. My team and I are leaving no stone unturned to ensure that BioAsia 2024 is grand and impactful. It’s not just an event; it’s a culmination of two decades of excellence. Together, let’s shape the future of healthcare.”
Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana, echoed this sentiment, highlighting BioAsia’s unmatched role in renewing emphasis on the life sciences industry over the past 20 editions. He emphasized the event’s impact on sparking attention from regulation, corporates, startups, and allied sectors.
Shakthi Nagappan, Director of Life Sciences, Govt. of Telangana and CEO of BioAsia, stated, “The 21st edition of BioAsia is certainly going to be a milestone event, as the presence of global leaders marks the vision to bridge the gaps in the healthcare industry and foster innovation in these critical sectors.”
EY, serving as the knowledge partner, will play a pivotal role in steering the event’s focus on themes such as Transformative Innovation in R&D, Patent Paradox: India’s Bid for Global R&D Dominance & IP Dilemmas, Leading the Health-tech Revolution – The Next Normal, India at the Frontier of Pharma Services, and MedTech as the Place to Be, among others.
The comprehensive agenda aims to address industry challenges and opportunities in the current times. With its global reach and diverse participation, BioAsia 2024 is set to facilitate knowledge exchange, collaboration, and innovation in the life sciences and biotechnology sector. As the countdown begins, anticipation is high for BioAsia 2024 to leave a lasting mark on the healthcare industry and contribute to shaping the future of these critical sectors.